| Deblaquiere Enterprises Inc | |
| 5453 Highway 2, Priest River, Idaho 83856 | |
| (208) 448-1633 |
| Name | Deblaquiere Enterprises Inc |
|---|---|
| Organization Name | Deblaquiere Enterprises Inc |
| Location | 5453 Highway 2, Priest River, Idaho 83856 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (208) 448-1633 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director's Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.
Results presented recently at the 6th Annual Conference of the International Society of Behavioural Nutrition and Physical Activity in Oslo, Norway, and soon to be published in the International Journal of Obesity reveal that 95 per cent of Australian adults are not meeting national physical activity and nutrition guidelines for health benefits.
› Verified 5 days ago
| NPI Number | 1285621136 |
| Organization Name | DEBLAQUIERE ENTERPRISES, INC. |
| Doing Business As | WHITE CROSS PHARMACY PRIEST RIVER |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 5453 Highway 2, Priest River, ID 83856 |
| Phone Number | 208-448-1633 |
News Archive
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director's Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.
Results presented recently at the 6th Annual Conference of the International Society of Behavioural Nutrition and Physical Activity in Oslo, Norway, and soon to be published in the International Journal of Obesity reveal that 95 per cent of Australian adults are not meeting national physical activity and nutrition guidelines for health benefits.
› Verified 5 days ago
News Archive
The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.
Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director's Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.
Results presented recently at the 6th Annual Conference of the International Society of Behavioural Nutrition and Physical Activity in Oslo, Norway, and soon to be published in the International Journal of Obesity reveal that 95 per cent of Australian adults are not meeting national physical activity and nutrition guidelines for health benefits.
› Verified 5 days ago
Deblaquiere Enterprises Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5453 Highway 2, Priest River, Idaho 83856 Phone: (208) 448-1633 | |
Priest River Eye Care Type: Medicare Supplier Location: 6132 Highway 2, Priest River, Idaho 83856 Phone: (208) 448-0144 |